Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective
2024 · Lung Cancer · 11 citations
https://doi.org/10.1016/j.lungcan.2024.107950